Steven Kuppens

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

Ola Landgren, Ajai Chari, Yaël C. Cohen et al. · Leukemia · 2020 · 98 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5)

Dominik Dytfeld, Binod Dhakal, Mounzer Agha et al. · Blood · 2021 · 41 citations

Pharmacy, Hematology, Pharmacotherapy +16

DVRd Followed By Ciltacabtagene Autoleucel Versus DVRd Followed By ASCT in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible: A Randomized Phase 3 Study (<i>EM</i>agine/CARTITUDE-6)

Mario Boccadoro, Jesús F. San Miguel, Kenshi Suzuki et al. · Blood · 2022 · 21 citations

Medicine, Internal Medicine, Oncology +13

Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA.

S. Vincent Rajkumar, Peter M. Voorhees, Hartmut Goldschmidt et al. · Journal of Clinical Oncology · 2018 · 11 citations

Medicine, Pharmacology, Pharmacotherapy +17